Pancreatic cancer
Conditions
Interventions
Case series:S-1monotherapy oral
Sponsors
Tongji Medical College Affiliated Hospital of Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Participants had to satisfy all of the following criteria: 1) age 18 to 75 years old; 2) Patients is confirmed by pathology/cytology examination as pancreatic ductal adenocarcinoma with Stage I/II/III; 3) the surgical margin is R0/R1; 4) ECOG 0-1; 5) rejection of intravenous chemotherapy after surgery; 6) Patients haven't recived tuogiosa(S-1) before,and recive tuogiosa(S-1) in 10 weeks after surgery,80~120 mg/day oral,day1 to day 28, and take two weeks off,every 6 weeks as a cycle,up to six months; 7) with appropriate organ function as follows:(the blood chemistry and blood biochemistry examination should be completed by 14 days before the date of the case: WBC=3.5*10^9/L; neutrophils=2*10^9/L; Hemoglobin=9g/dL; Platelets=10*10^9/L; Total bilirubin<1.5 times compared with normal value upper limit(ULN); Liver function index(AST&ALT) chemical examination <2.5 times than normal value upper limit(ULN); serum creatine =1.2mg/dL and creatinine clearance rate =50ml/min(24-hour urine collection or use Cockroft-Gault method); 8) Participants who satisfy all of the criteria should sign the informed consent form at first after knowing the details of the experiment.
Exclusion criteria
Exclusion criteria: Participants who meet any of the following are not eligible for the study: 1) pulmonary fibrosis or interstitial pneumonia was diagnosed within 28 days before the case; 2) serious diarrhea; 3) existing infection; 4) major coexisting diseases,including (but not limited to) heart failure, renal failure,liver failure,hemorrhagic peptic ulcer,intestinal paralysis,intestinal obstruction or uncontrolled diabetes; 5) moderate or severe ascites or pleural effusion need drainage; 6) serious mental illness; 7) Participants who have other cancers without situ cervical cancer or basal skin cancer within 3 years,include the people that have other cancers and the disease free survival more than 5 years; 8) Patients treated with fluorouracil, phenytoin or warfarin; 9) Serious mental problems; 10) Other situations that the researchers considered inappropriate for inclusion in this study based on safety considerations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Disease free survival; | — |
Countries
China
Contacts
Public ContactWu Heshui
Tongji Medical College Affiliated Hospital of Huazhong University of Science and Technology
Outcome results
None listed